In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of Radiology and European Respiratory Society joint white paper on lung cancer screening (LCS) in 2015, many new findings have been published and discussions have increased considerably. Thus, this updated expert opinion represents a narrative, non-systematic review of the evidence from LCS trials and description of the current practice of LCS as well as aspects that have not received adequate attention until now. Reaching out to the potential participants (persons at high risk), optimal communication and shared decision-making will be key starting points. Furthermore, standards for infrastructure, pathways and quality assurance are pivotal, including promoting tobacco cessation, benefits and harms, overdiagnosis, quality, minimum radiation exposure, definition of management of positive screen results and incidental findings linked to respective actions as well as cost-effectiveness. This requires a multidisciplinary team with experts from pulmonology and radiology as well as thoracic oncologists, thoracic surgeons, pathologists, family doctors, patient representatives and others. The ESR and ERS agree that Europe's health systems need to adapt to allow citizens to benefit from organised pathways, rather than unsupervised initiatives, to allow early diagnosis of lung cancer and reduce the mortality rate. Now is the time to set up and conduct demonstration programmes focusing, among other points, on methodology, standardisation, tobacco cessation, education on healthy lifestyle, cost-effectiveness and a central registry. The ESR and ERS agree that Europe’s healthcare systems need to allow citizens to benefit from organised pathways to early diagnosis and reduction of mortality of lung cancer. Now is the time to set up and implement large-scale programmes. http://bit.ly/2miF0cO

中文翻译：

---

关于肺癌筛查的 ESR/ERS 声明文件

在欧洲，肺癌在最常见的癌症中排名第三，仍然是最大的杀手。自 2015 年欧洲放射学会和欧洲呼吸学会首份肺癌筛查（LCS）联合白皮书发表以来，发表了许多新发现，讨论也大大增加。因此，此更新的专家意见代表了对 LCS 试验证据的叙述性、非系统性审查，并描述了 LCS 的当前实践以及迄今为止尚未受到足够重视的方面。接触潜在参与者（高危人群）、最佳沟通和共同决策将是关键起点。此外，基础设施、途径和质量保证的标准至关重要，包括促进戒烟、益处和危害、过度诊断、质量、最低辐射暴露、阳性筛查结果管理的定义和与各自行动相关的偶然发现以及成本效益。这需要一个由肺病学和放射学专家以及胸腔肿瘤学家、胸外科医生、病理学家、家庭医生、患者代表等组成的多学科团队。ESR 和 ERS ​​一致认为，欧洲的卫生系统需要进行调整，让公民从有组织的途径中受益，而不是不受监督的举措，以实现肺癌的早期诊断并降低死亡率。现在是建立和开展示范项目的时候了，重点是方法论、标准化、戒烟、健康生活方式教育、成本效益和中央登记。ESR 和 ERS ​​一致认为，欧洲的医疗保健系统需要允许公民从有组织的途径中受益，以实现肺癌的早期诊断和降低死亡率。现在是建立和实施大规模计划的时候了。http://bit.ly/2miF0cO